A Prospective Multi-centre, Non-interventional, observational Post Marketing Surveillance (PMS) Study of AdaliRelTM (Adalimumab) to Evaluate long-term safety in Patients With Active Rheumatoid arthritis in Routine Clinical Practice
Latest Information Update: 31 Jul 2020
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Reliance Life Sciences
Most Recent Events
- 31 Jul 2020 New trial record